Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
Clicks: 366
ID: 115822
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
80.5
/100
366 views
262 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #6 of 11 articles by views in clinical cancer research : an official journal of the american association for cancer research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Everolimus, letrozole, and metformin resulted in 50% CB and 28% OR in women with recurrent EEC. Progesterone receptor-positive tumors may have better response; validation studies are needed.See related commentary by Madariaga et al., p. 523.
| Reference Key |
pt2020clinicaleverolimus,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Soliman PT;Westin SN;Iglesias DA;Fellman BM;Yuan Y;Zhang Q;Yates MS;Broaddus RR;Slomovitz BM;Lu KH;Coleman RL;; |
| Journal | clinical cancer research : an official journal of the american association for cancer research |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.